Abstract:Introduction: Eravacycline (ERV), a novel tetracycline derivative, exhibits broad-spectrum antibacterial activity, but data on the bacterial activity against Chinese bacterial isolates are very scarce. This study aims to evaluate the activity of eravacycline against the common Gram-positive and Gram-negative bacteria isolates in Guangdong, China. Methods: The clinical isolates were collected from four centers between 1 November 2023 and 31 January 2024, and the susceptibility of eravacycline (MIC 50 , MIC 90 , and MIC) was determined using broth microdilution as a reference method and E-TEST strips to evaluate their consistency. A total of 594 strains were collected from the four centers, including Staphylococcus aureus ( n = 126), Enterococcus faecalis ( n = 58), Enterococcus faecium ( n = 29), Klebsiella pneumoniae ( n = 136), Escherichia coli ( n = 187), and Acinetobacter baumannii ( n = 58). Results and discussion: The MIC 50 and MIC 90 (mg/L) of eravacycline were 0.12 and 1 for S. aureus, 0.06 and 0.12 for E. faecalis , 0.06 and 0.5 for E. faecium , 0.25 and 0.5 for E. coli , 0.5 and 2 for K. pneumoniae , and 0.25 and 2 for A. baumannii . Based on the FDA and EUCAST breakpoints, the susceptibility of eravacycline against S. aureus was 46.03% vs. 83.33%, 56.90% vs. 94.93% against E. faecalis , and 62.07% vs. 79.31% in E. faecium . The susceptibility rates of E. coli and K. pneumoniae were 90.37% and 58.09, respectively. To evaluate the performance between the broth microdilution test (BMD) and ETEST methods, we compared essential agreement (EA), categorical agreement (CA), very major error (VME), and major error (ME). The results demonstrated that compared with BMD, eravacycline measured by ETEST had higher VME and ME referring to FDA breakpoints than EUCAST breakpoints in the Gram-positive isolates. Since there were no intermediate breakpoints for the eravacycline, the MIC values measured by the ETEST method might result in lower CA and higher VME and ME. This study provides MIC values of eravacycline against Gram-positive and Gram-negative pathogens in four hospitals in Guangdong Province, and eravacycline is an effective therapeutic candidate for common bacteria.

Study on the in vivo antimicrobial activities of clarithromycin

Synthesis and Antibacterial Evaluation of Novel Clarithromycin Derivatives with C-4″ Elongated Arylalkyl Groups Against Macrolide-Resistant Strains.

Study on the in vitro antibacterial activities of the antibacterial drugs against methicillin resistant coagulase-negative staphylococci

Design, synthesis and antibacterial evaluation of novel C-11, C-9 or C-2'-substituted 3-O-descladinosyl-3-ketoclarithromycin derivatives

Pharmacodynamic assessment of clarithromycin in a murine model of pneumococcal pneumonia

Synthesis and antibacterial activity of novel 11-[3-[(arylcarbamoyl)oxy]propylamino]-11-deoxy-6-O-methyl-3-oxoerythromycin A 11-N,12-O-cyclic carbamate derivatives

Analysis on Antibacterial Activity of Chloramphenicol and Rifampin to Mycoplasma Pneumoniae

In vitro activities of Eravacycline against 336 isolates collected from 2012 to 2016 from 11 teaching hospitals in China

In vitro antibacterial activity of DX-619, a novel Des-F (6)-quinolone against clinical isolates in China.

In vitro activity of domestic roxithromycin

The Effect of Erythromycin in Macrolide-Resistant Bordetella pertussis: Inhibitory Effect on Growth, Toxin Expression, and Virulence

In Vitro Assessment of 17 Antimicrobial Agents Against Clinical Mycobacterium Avium Complex Isolates

Design, synthesis and biological evaluation of pleuromutilin-Schiff base hybrids as potent anti-MRSA agents in vitro and in vivo

The anti-biofilm effect of macrolides in a rat model of S. aureus foreign-body infection: Might it be of clinical relevance?

In vitro activities of eravacycline against clinical bacterial isolates: a multicenter study in Guangdong, China

Relationship between clarithromycin MICs and treatment responses in Mycobacterium avium complex pulmonary disease

In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates

Antimicrobial activity of eravacycline and other comparative agents on aerobic and anaerobic bacterial pathogens in Taiwan: a clinical microbiological study

Influence of clarithromycin on biofilm of Pseudomonas aeruginosa

In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.

Design, Synthesis and Structure-activity Relationships of Novel Non-ketolides: 9-Oxime Clarithromycin Featured with Seven- to Thirteen-atom-length Diamine Linkers at 3-OH